News archive
Showing 754 results
December 2020
-
Media Release
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
-
Media Release
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1 Kisqali plus endocrine therapy had a median OS of nearly five years (58.7… -
Media Release
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
-
Media Release
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase… -
Media Release
Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine
-
Media Release
Novartis and Amgen partner with Karamo Brown to support and empower people living with migraine
The Know Migraine Mission initiative seeks to challenge misconceptions and start new conversations about migraine Karamo Brown to connect directly with people affected by migraine to share… -
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for adults with nasal polyps
Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation Xolair is now FDA-approved across three diseases and in…
November 2020
-
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
-
Media Release
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs. bosutinib in CML patients previously treated with two or more TKIs ELARA results for Kymriah® in relapsed or… -
Media Release
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
-
Media Release
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17, regardless of age and gender
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult…